Industry
Biotechnology
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
6.33
Mkt cap
386M
Volume
420K
High
6.39
P/E Ratio
-1.13
52-wk high
28.26
Low
6.17
Div yield
N/A
52-wk low
5.64
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 8:44 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 6:50 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 4:43 pm
Portfolio Pulse from Benzinga Insights
October 30, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 4:02 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 3:36 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 3:21 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 2:02 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 9:31 am
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 8:15 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.